Megan Hollasch

3 days ago | onclive.com | Megan Hollasch

Several targeted chimeric antigen receptor (CAR) T-cell therapies are beginning to show early signals of efficacy for patients with solid tumors as investigators are working to translate the efficacy and safety profiles seen with these agents in hematologic malignancies to the solid tumor field. Among them are satricabtagene autoleucel (satri-cel; CT041),1,2 autologous GD2-CART,3 ALLO-316,4 GCC19CART,5 and more, according to recent data.

1 week ago | onclive.com | Megan Hollasch

The next-generation antibody-drug conjugate (ADC) ARX788 generated excitement when it received fast track designation from the FDA for patients with HER2-positive metastatic breast cancer and again when it yielded a significant improvement in progression-free survival (PFS) vs lapatinib (Tykerb) plus capecitabine and showed a trend toward overall survival (OS) improvement.1,2 Differing from the topoisomerase I inhibitor payload of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu), ARX788 has...

1 month ago | onclive.com | Megan Hollasch |Ashling Wahner

Each research step that reveals patterns of activity with targeted therapies in endometrial cancer—such as metformin and temsirolimus (Torisel)—brings the field closer to developing increasingly effective and better-tolerated regimens that improve upon historical treatment results and quality of life (QOL) outcomes, according to Pamela T. Soliman, MD, MPH.

1 month ago | onclive.com | Megan Hollasch

Putting an emphasis on immunohistochemistry (IHC) staining is top of mind as fam-trastuzumab deruxtecan-nxki (Enhertu, T-DXd) sits alongside tisotumab vedotin-tftv (Tivdak) as options in the second-line cervical cancer setting. Unlike the tissue factor–directed antibody-drug conjugate (ADC), the HER2-targeted ADC does not hold an all-comer indication and is only applicable for a select few patients.

1 month ago | onclive.com | Megan Hollasch

CommentaryArticleApril 7, 2025Fact checked by:Tanios S. Bekaii-Saab, MD, details studies of ctDNA-guided strategies that are elucidating the role of adjuvant therapies in CRC and agents of promise.